Siga Technologies (NSDQ:SIGA) said today that it signed a multi-year contract with the Biomedical Advanced Research & Development Authority to provide oral and intravenous versions of Siga’s Tpoxx smallpox treatment to the Strategic National Stockpile.
The contract, which is valued at up to $629 million, also includes funding for advanced development of the the drug’s IV formulation and post-marketing activities for Tpoxx’s oral formulation.
Get the full story at our sister site, Drug Delivery Business News.
The post Siga lands $629m BARDA contract to stockpile smallpox treatment appeared first on MassDevice.